Skip to main content

Table 2 Summary of immunohistochemical abnormalities in different lesions

From: Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma

   

Precursor lesions*

ESCC*

P-value

Protein

 

Normal

Low#

High##

I

IIA/IIB

III/IV

P a

P b

P c

P d

P e

P f

 

-

22(11.8%)

28(65.1%)

71(62.8%)

14(77.8%)

42(55.3%)

56(57.7%)

      

Fas

+

89(46.6%)

13(30.2%)

31(27.4%)

4(22.2%)

30(39.5%)

31(32.0%)

<0.001

<0.001

0.583

0.295

0.184

0.355

 

++

76(40.6%)

2(4.7%)

11(9.7%)

0

4(5.3%)

10(10.3%)

      
 

-

155(84.7%)

15(38.5%)

28(23.5%)

1(5.6%)

36(44.4%)

58(59.2%)

      

FADD

+

25(13.7%)

20(51.3%)

56(47.1%)

11(61.1%)

40(49.4%)

28(28.6%)

<0.001

<0.001

0.032

0.212

<0.001

0.013

 

++

3(1.6%)

4(10.3%)

35(29.4%)

6(33.3%)

5(6.2%)

12(12.2%)

      
 

-

72(39.1%)

40(100%)

114(100%)

18(100%)

81(100%)

98(100%)

      

Caspase 8

+

76(41.3%)

0

0

0

0

0

------

------

------

------

------

------

 

++

36(19.6%)

0

0

0

0

0

      
 

-

102(53.4%)

9(21.4%)

47(38.5%)

3(16.7%)

30(37.0%)

30(30.6%)

      

CDC25B

+

76(39.8%)

26(61.9%)

45(36.9%)

5(27.8%)

43(53.1%)

59(60.2%)

<0.001

0.001

0.018

0.021

<0.001

0.618

 

++

13(6.8%)

7(16.7%)

30(24.6%)

10(55.6%)

8(9.9%)

9(9.2%)

      
 

-

152 ** (82.2%)

9(20.5%)

14(11.7%)

2(11.8%)

16(19.8%)

16(16.3%)

      

Fascin

+

17(9.2%)

23(52.3%)

62(51.7%)

6(35.3%)

29(35.8%)

43(43.9%)

<0.001

<0.001

0.272

0.402

0.701

0.203

 

++

16(8.6%)

12(27.3%)

44(36.7%)

9(52.9%)

36(44.4%)

39(39.8%)

      
 

-

159**(86.9%)

30(78.9%)

65(59.0%)

13(68.4%)

29(35.8%)

33(34.0%)

      

CK14

+

16(8.7%)

5(13.2%)

29(26.4%)

3(15.8%)

12(14.8%)

24(24.7%)

<0.001

0.436

0.035

0.612

0.019

0.241

 

++

8(4.4%)

3(7.9%)

16(14.5%)

3(15.8%)

40(49.4%)

40(41.2%)

      
 

-

5(2.8%)

39(86.7%)

85(70.2%)

18(94.7%)

39(48.8%)

49(49.5%)

      

CK4

+

123(68.0%)

6(13.3%)

34(28.1%)

1(5.3%)

39(48.8%)

46(46.5%)

<0.001

<0.001

0.020

0.079

0.001

0.832

 

++

53(29.3%)

0

2(1.7%)

0

2(2.5%)

4(4.0%)

      
 

-

1(0.5%)

24(53.3%)

52(43.3%)

10(52.6%)

44(55.7%)

58(58.6%)

      

Annexin 1

+

48(26.0%)

16(35.6%)

46(38.3%)

6(31.6%)

30(38.0%)

30(30.3%)

<0.001

<0.001

0.402

0.749

0.391

0.377

 

++

136(73.5%)

5(11.1%)

22(18.3%)

3(15.8%)

5(6.3%)

11(11.1%)

      
 

-

181***(100%)

37(88.1%)

88(74.6%)

6(37.5%)

26(32.1%)

22(22.4%)

      

Laminin-5γ2

+

0

5(11.9%)

29(24.6%)

6(37.5%)

46(56.8%)

56(57.1%)

------

------

0.181

<0.001

0.227

0.142

 

++

0

0

1(0.8%)

4(25%)

9(11.1%)

20(20.4%)

      
 

-

167(96.0%)

40(95.2%)

116(97.5%)

10(71.4%)

13(18.3%)

11(11.6%)

<0.001

0.651

0.606

<0.001

<0.001

0.125

SPARC in stromal fibroblasts

+

5(2.9%)

2(4.8%)

3(2.5%)

3(21.4%)

28(39.4%)

29(30.5%)

      
 

++

2(1.1%)

0

0

1(7.1%)

30(42.3%)

55(57.9%)

      
 

-

174(100%)

42(95.5%)

117(96.7%)

18(100%)

76(93.8%)

90(91.8%)

      

SPARC in epithelial cells

+

0

2(4.5%)

4(3.3%)

0

3(3.7%)

3(3.1%)

------

------

------

------

------

------

 

++

0

0

0

0

2(2.5%)

5(5.1%)

      
  1. *Numbers of valid (informative) cases.
  2. **Including cases of only basal cells positive labeling.
  3. ***Only basal membrane positive labeling in normal epithelia.
  4. #Low: Mild & Moderate DYS; ##High: Severe DYS & CIS.
  5. aEsophageal normal epithelia vs. ESCC. bEsophageal normal epithelia vs. Mild & Moderate DYS. cMild & Moderate DYS vs. Severe DYS & CIS. dSevere DYS & CIS vs. ESCC stage I. eESCC stage I vs. ESCC stage II. fESCC stage II vs. ESCC stage III & IV.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us